Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Income: 2010-2025

Historic Operating Income for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Operating Income rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$11.5 million for FY2024, which is 89.58% up from last year.
  • As of Q3 2025, Heron Therapeutics' Operating Income stood at -$4.1 million, which was down 150.03% from -$1.6 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Operating Income high stood at $4.2 million for Q4 2024, and its period low was -$62.9 million during Q1 2022.
  • Its 3-year average for Operating Income is -$11.3 million, with a median of -$4.8 million in 2024.
  • As far as peak fluctuations go, Heron Therapeutics' Operating Income fell by 20.74% in 2022, and later skyrocketed by 165.74% in 2025.
  • Heron Therapeutics' Operating Income (Quarterly) stood at -$53.5 million in 2021, then skyrocketed by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then spiked by 140.83% to $4.2 million in 2024, then climbed by 8.19% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$1.6 million for Q2 2025, and $3.2 million during Q1 2025.